Bradford Biotech Start-Up Recognised Among UK’s Top 17

Local company Hado Therapeutics joins national accelerator programme

A Bradford-based biotech start-up has been named among the top 17 most promising companies nationally in a government-backed initiative aimed at advancing the future of medicines. Hado Therapeutics, supported by the University of Bradford’s Enterprise Fellowship Programme, has secured a place on the LYVA Labs Future Medicines Accelerator. This programme is part of the Innovate UK Biomedical Catalyst Accelerator, which seeks to fast-track innovative biotech ventures across the UK.

About Hado Therapeutics

Hado Therapeutics focuses on developing novel dual-targeting molecules designed to act on multiple disease pathways. This approach aims to increase the chances of clinical success and address areas with significant unmet medical needs. The company’s current research pipeline includes projects targeting Parkinson’s disease and glioblastoma, an aggressive form of brain cancer. These efforts position both Hado Therapeutics and Bradford as contributors to next-generation therapeutic developments.

University of Bradford’s Role

The University of Bradford supports Hado Therapeutics through its Enterprise Fellowship Programme and the Institute of Cancer Therapeutics. The Enterprise Fellowship Programme assists academics and researchers in transforming their ideas into commercially viable ventures by providing time, structure, and entrepreneurial support. It forms part of the Bradford Renduchintala Enterprise Ecosystem (BREE), which offers a range of enterprise support programmes for ventures at various stages, from student-led start-ups to early-stage research commercialisation.

Statements from Key Figures

• Dr Harsha Kantamneni, CEO and co-founder of Hado Therapeutics, described the selection for the Innovate UK Biomedical Catalyst Accelerator as a prestigious milestone. He highlighted the importance of the University’s support in fostering sustainable growth through scientific collaboration.
• Professor Sherif El-Khamisy, Pro Vice Chancellor at the University of Bradford, expressed pride in Hado Therapeutics’ recognition. He noted that the achievement reflects the quality of scientific research and enterprise programmes at Bradford, which contribute to addressing global health challenges.
• Sonya Bachra Byrne, Enterprise Development Manager, emphasised the role of the Enterprise Fellowship Programme in helping innovators develop commercially credible ventures and strengthen entrepreneurial skills, contributing to a culture of innovation within the University.

The inclusion of Hado Therapeutics in the LYVA Labs Future Medicines Accelerator highlights the ongoing efforts within Bradford to support biotech innovation and contribute to advancements in medical research and treatment development.